Olaf Mercier Selected Research

Heart-Lung Transplantation

10/2021	Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program.
8/2017	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension.
7/2016	Extracorporeal Life Support After Pulmonary Endarterectomy as a Bridge to Recovery or Transplantation: Lessons From 31 Consecutive Patients.
10/2014	Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group.
9/2010	Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Olaf Mercier Research Topics

Disease

33	Pulmonary Hypertension 03/2022 - 02/2008
18	Pulmonary Arterial Hypertension 01/2022 - 07/2008
16	Neoplasms (Cancer) 01/2021 - 08/2009
12	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 07/2005
7	Neoplasm Metastasis (Metastasis) 01/2019 - 05/2008
6	Heart Failure 01/2022 - 09/2011
6	Lung Neoplasms (Lung Cancer) 01/2022 - 05/2008
6	Hypoxia (Hypoxemia) 01/2022 - 01/2014
4	Pulmonary Embolism 01/2022 - 10/2013
4	Infections 01/2022 - 12/2015
4	Inflammation (Inflammations) 01/2021 - 09/2011
4	Hypertrophy 05/2016 - 06/2009
4	Familial Primary Pulmonary Hypertension 07/2013 - 07/2008
3	Connective Tissue Diseases (Connective Tissue Disease) 01/2022 - 10/2020
3	Fibrosis (Cirrhosis) 01/2018 - 11/2014
2	Congenital Heart Defects (Congenital Heart Defect) 10/2021 - 11/2020
2	Shock 01/2021 - 01/2021
2	COVID-19 01/2021 - 11/2020
2	Idiopathic Pulmonary Fibrosis 06/2020 - 11/2014
2	Right Ventricular Hypertrophy 01/2020 - 01/2013
2	Heart Diseases (Heart Disease) 01/2020 - 04/2018
2	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2018 - 10/2014
2	Respiratory Insufficiency (Respiratory Failure) 07/2016 - 10/2013
1	Atrial Heart Septal Defects (Atrial Septal Defect) 01/2022
1	Sepsis (Septicemia) 01/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Hemorrhagic Shock 01/2022
1	Thrombosis (Thrombus) 01/2022
1	Embolism (Embolus) 01/2022
1	Cystic Fibrosis (Mucoviscidosis) 11/2021
1	Aspergillosis 03/2021
1	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders) 01/2021
1	Fibroma (Fibromatosis) 12/2020
1	Aggressive Fibromatosis (Desmoid) 12/2020
1	Scimitar Syndrome 11/2020
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 11/2020
1	Disease Progression 06/2020

Drug/Important Bio-Agent (IBA)

6	MonocrotalineIBA 11/2021 - 09/2011
4	Biological ProductsIBA 01/2022 - 08/2009
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2009
3	Dobutamine FDA LinkGeneric 01/2022 - 12/2017
3	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2021 - 03/2017
3	Dihydrotachysterol (AT 10)IBA 01/2018 - 01/2006
2	salicylhydroxamic acid (SHAM)IBA 01/2022 - 03/2019
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2022 - 01/2021
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 11/2021 - 11/2014
2	Pharmaceutical PreparationsIBA 10/2020 - 06/2015
2	Peptides (Polypeptides)IBA 01/2020 - 12/2018
2	Type II Bone Morphogenetic Protein Receptors (Bone Morphogenetic Protein Receptor Type II)IBA 01/2018 - 05/2016
2	Phosphotransferases (Kinase)IBA 01/2018 - 01/2014
2	Interleukin-6 (Interleukin 6)IBA 03/2017 - 01/2014
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 03/2017 - 01/2014
2	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 12/2016 - 05/2016
2	TitaniumIBA 01/2014 - 12/2012
2	Endothelin-1 (Endothelin 1)IBA 09/2010 - 06/2009
2	Biomarkers (Surrogate Marker)IBA 10/2009 - 08/2009
1	Polytetrafluoroethylene (Teflon)FDA Link 01/2022
1	ProstaglandinsIBA 01/2022
1	AlbuminsIBA 01/2022
1	Diazoxide (Hyperstat)FDA Link 01/2022
1	Saline SolutionIBA 01/2022
1	FibrinIBA 01/2022
1	SodiumIBA 01/2022
1	pro-brain natriuretic peptide (1-76)IBA 01/2022
1	Gonadal Steroid Hormones (Sex Hormones)IBA 01/2022
1	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 11/2021
1	C-Reactive ProteinIBA 01/2021
1	Uric Acid (Urate)IBA 01/2021
1	urate transporterIBA 01/2021
1	Xanthine OxidaseIBA 01/2021
1	Vinorelbine (Navelbine)FDA LinkGeneric 12/2020
1	EnbucrilateIBA 11/2020
1	Vasodilator Agents (Vasodilators)IBA 11/2020
1	Immune Checkpoint InhibitorsIBA 10/2020
1	Antifibrotic AgentsIBA 06/2020
1	beta CateninIBA 06/2020
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2020
1	CalciumIBA 01/2020
1	Potassium Channels (Potassium Channel)IBA 01/2020
1	AcidsIBA 01/2020
1	LipidsIBA 01/2020
1	15-hydroxy-5,8,11,13-eicosatetraenoic acidIBA 01/2020

Therapy/Procedure

16	Therapeutics 03/2022 - 07/2005
14	Lung Transplantation 01/2022 - 09/2010
11	Endarterectomy (Thromboendarterectomy) 03/2022 - 02/2008
6	Radiotherapy 01/2022 - 11/2016
5	Heart-Lung Transplantation 10/2021 - 09/2010
5	Transplantation 10/2021 - 10/2014
4	Extracorporeal Membrane Oxygenation 01/2022 - 12/2017
4	Pneumonectomy (Lung Volume Reduction) 11/2014 - 01/2006
3	Ligation 01/2022 - 04/2012
3	Cardiopulmonary Bypass (Heart-Lung Bypass) 11/2020 - 09/2014
3	Operative Surgical Procedures 09/2014 - 08/2012
2	Drug Therapy (Chemotherapy) 01/2022 - 07/2012
2	Resuscitation 01/2022 - 01/2021
2	Immunotherapy 10/2020 - 12/2018
2	Contraindications 10/2014 - 01/2006
2	Stents 10/2013 - 07/2009
1	Oxygenators 01/2022
1	Thoracotomy 01/2022